JP6049216B2 - メタボリック症候群の処置のための化合物 - Google Patents

メタボリック症候群の処置のための化合物 Download PDF

Info

Publication number
JP6049216B2
JP6049216B2 JP2014501607A JP2014501607A JP6049216B2 JP 6049216 B2 JP6049216 B2 JP 6049216B2 JP 2014501607 A JP2014501607 A JP 2014501607A JP 2014501607 A JP2014501607 A JP 2014501607A JP 6049216 B2 JP6049216 B2 JP 6049216B2
Authority
JP
Japan
Prior art keywords
linear
formula
compound
carbons
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014501607A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014510741A5 (enExample
JP2014510741A (ja
Inventor
ナバハス，ホアン カルロス アグレダ
ナバハス，ホアン カルロス アグレダ
カッスヤ，ロベルト ミキオ
カッスヤ，ロベルト ミキオ
Original Assignee
エスジェイティー モレキュラー リサーチ，エス．エル．
エスジェイティー モレキュラー リサーチ，エス．エル．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エスジェイティー モレキュラー リサーチ，エス．エル．, エスジェイティー モレキュラー リサーチ，エス．エル． filed Critical エスジェイティー モレキュラー リサーチ，エス．エル．
Publication of JP2014510741A publication Critical patent/JP2014510741A/ja
Publication of JP2014510741A5 publication Critical patent/JP2014510741A5/ja
Application granted granted Critical
Publication of JP6049216B2 publication Critical patent/JP6049216B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A23L33/165—Complexes or chelates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/69—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing fluorine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/326—Foods, ingredients or supplements having a functional effect on health having effect on cardiovascular health
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/3262—Foods, ingredients or supplements having a functional effect on health having an effect on blood cholesterol
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/332—Promoters of weight control and weight loss
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/92—Oral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pediatric Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cosmetics (AREA)
JP2014501607A 2011-03-28 2012-03-28 メタボリック症候群の処置のための化合物 Active JP6049216B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161468163P 2011-03-28 2011-03-28
US61/468,163 2011-03-28
PCT/EP2012/055570 WO2012130912A1 (en) 2011-03-28 2012-03-28 Compounds for treatment of metabolic syndrome

Publications (3)

Publication Number Publication Date
JP2014510741A JP2014510741A (ja) 2014-05-01
JP2014510741A5 JP2014510741A5 (enExample) 2015-05-21
JP6049216B2 true JP6049216B2 (ja) 2016-12-21

Family

ID=45974264

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014501607A Active JP6049216B2 (ja) 2011-03-28 2012-03-28 メタボリック症候群の処置のための化合物

Country Status (16)

Country Link
US (2) US9440966B2 (enExample)
EP (1) EP2691394B1 (enExample)
JP (1) JP6049216B2 (enExample)
KR (1) KR101784284B1 (enExample)
CN (2) CN103596949A (enExample)
AU (1) AU2012234230B2 (enExample)
BR (1) BR112013024602A2 (enExample)
CA (1) CA2831716C (enExample)
DK (1) DK2691394T3 (enExample)
ES (1) ES2635415T3 (enExample)
IL (1) IL228630A (enExample)
MX (1) MX349254B (enExample)
PL (1) PL2691394T3 (enExample)
PT (1) PT2691394T (enExample)
RU (1) RU2615136C2 (enExample)
WO (1) WO2012130912A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106317180B (zh) * 2015-06-24 2019-09-13 首都医科大学 β-咔啉-3-甲酰-Orn-AA-NHCH2C6H5其合成，活性和应用
WO2018142379A1 (en) 2017-02-06 2018-08-09 Joslin Diabetes Center, Inc. Methods and compositions for treating metabolic disorders
US10857136B2 (en) 2017-03-14 2020-12-08 Sjt Molecular Research, Sl Compounds for use in the prevention and/or treatment of non-alcoholic fat liver disease and non-alcoholic steatohepatitis
CN109134460B (zh) * 2018-08-02 2021-04-06 南开大学 一种β-咔啉类化合物的合成方法
CN109628358B (zh) 2019-02-20 2021-03-19 无限极（中国）有限公司 一种复合益生菌及其应用
CN109666615B (zh) 2019-02-20 2021-03-19 无限极（中国）有限公司 一种益生菌组合物及其应用
CN110585202A (zh) * 2019-10-27 2019-12-20 淮安市厚沐医疗技术咨询中心 一种β-咔啉生物碱及其葡萄糖苷用于抑制肝脏糖异生的用途
WO2021195603A1 (en) * 2020-03-27 2021-09-30 Virginia Polytechnic Institute And State University Anti-malarial compounds and uses thereof
CN111892596B (zh) * 2020-08-28 2022-07-15 南通大学 含多氟吡唑结构的β-咔啉类化合物的制备和应用
CN112047940B (zh) * 2020-08-28 2021-06-29 南通大学 含1-(3,4-二甲氧基苯基)-β-咔啉单元的吡唑化合物的制备与用途
CN116675689A (zh) * 2023-05-05 2023-09-01 五邑大学 一种β-咔啉类衍生物及其制备方法和应用
CN117700409A (zh) * 2023-05-16 2024-03-15 赣南医学院 一种用于降血脂的药物及其制备方法和应用
CN119613401B (zh) * 2024-11-04 2025-09-09 兰州大学第二医院 一种苯基哌嗪基β-咔啉类衍生物及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES273769A1 (es) 1961-01-18 1962-06-01 Geigy Ag J R Procedimiento para la preparaciën de nuevos derivados de amidas de acido beta-carbolin-carboxilico
EP1086101B1 (en) * 1998-06-12 2002-12-18 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Beta-carboline compounds
RU2271350C2 (ru) * 2000-06-09 2006-03-10 Санофи-Авентис Дойчланд Гмбх Производные ацилфенилмочевины, фармацевтическая композиция и способ ее получения
KR20060006031A (ko) * 2003-04-09 2006-01-18 밀레니엄 파머슈티컬스 인코퍼레이티드 염증 질환 치료에 유용한 베타-카르볼린
WO2008103470A2 (en) * 2007-02-21 2008-08-28 Trustees Of Columbia University In The City Of New York Oncogenic-ras-signal dependent lethal compounds
EP2033962A1 (en) * 2007-08-22 2009-03-11 4Sc Ag Tetracyclic indolopyridines as EG5 inhibitors
US8143269B2 (en) 2008-10-03 2012-03-27 Calcimedica, Inc. Inhibitors of store operated calcium release
US20100173931A1 (en) 2009-01-06 2010-07-08 Osteogenex Inc. Harmine derivatives for reducing body weight

Also Published As

Publication number Publication date
CA2831716C (en) 2018-06-12
CN107652283A (zh) 2018-02-02
BR112013024602A2 (pt) 2020-10-13
IL228630A (en) 2017-03-30
US9440966B2 (en) 2016-09-13
MX349254B (es) 2017-07-19
EP2691394A1 (en) 2014-02-05
CN103596949A (zh) 2014-02-19
AU2012234230B2 (en) 2016-12-01
EP2691394B1 (en) 2017-05-10
WO2012130912A1 (en) 2012-10-04
RU2615136C2 (ru) 2017-04-04
JP2014510741A (ja) 2014-05-01
CN107652283B (zh) 2021-07-06
IL228630A0 (en) 2013-12-31
MX2013011124A (es) 2014-03-31
DK2691394T3 (en) 2017-08-28
AU2012234230A1 (en) 2013-10-17
KR20140025401A (ko) 2014-03-04
ES2635415T3 (es) 2017-10-03
CA2831716A1 (en) 2012-10-04
US20150051204A1 (en) 2015-02-19
RU2013147629A (ru) 2015-05-10
KR101784284B1 (ko) 2017-10-11
US20160340355A1 (en) 2016-11-24
PT2691394T (pt) 2017-08-14
PL2691394T3 (pl) 2017-10-31

Similar Documents

Publication Publication Date Title
JP2014510741A (ja) メタボリック症候群の処置のための化合物
NO161802B (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive furo-(3,4-c)-pyridinderivater.
MC937A1 (fr) Procédé de préparations d'inhibiteurs de xanthine-oxydase
KR970005909B1 (ko) 치환된 2-페닐-4-퀴놀린카르복실산과 이의 제조방법
FI68048B (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara sustituerade oxirankarboxylsyror
US5124328A (en) Morpholine derivatives compositions and use
JPS6026388B2 (ja) ２−ヒドロキシメチル−３，４，５−トリヒドロキシ−ピペリジン誘導体、その製法及び利用
PT96251A (pt) Processo para a preparacao de imidazo{4,5-c}piridinas uteis como agentes anti-osteoporoticos
US5681843A (en) Parabanic acid derivatives
LU82797A1 (fr) Nouveaux amino-2 benzoyl-3 phenylacetamides et leurs homologues cycliques utiles comme medicaments et compositions therapeutiques et formes pharmaceutiques les contenant
FR2496663A1 (fr) Nouveaux derives de naphtyridine-1,8 utiles notamment comme medicaments antibacteriens
JPS63135378A (ja) ブチロラクトン誘導体、その製造方法およびその用途
CN102234284B (zh) 含氟的噻氯匹啶类似物及其制备方法和用途
JP4939761B2 (ja) 石蓮花の含有成分とその用途
CN116082239B (zh) Pde4/7双靶点抑制剂及其制备方法与应用
JP5792318B2 (ja) ブロムフェナク有機塩、ならびにその製造方法、組成物および使用
NO159588B (no) Analogifremgangsm te for fremstilling av terapeutisk aktive 5-okso-2-pyrrolidin-propansyrederivater.
IE51110B1 (en) 4-hydroxy-1,2-benzisothiazol-3(2h)-one-1.1-dioxide
CN108558843B (zh) 一种香豆素-三唑-靛红型化合物及其制备方法和应用
CN120794916A (zh) 一类2，4-二硝基苯氧基类化合物及其制备方法
JPS6176491A (ja) 新規なイソオキサゾロキノリン誘導体、製造のための方法および中間体、薬剤としての用途並びに薬剤含有組成物
FR2618431A1 (fr) Nouveaux thioethers de quinoleine, leur procede de preparation et compositions pharmaceutiques les contenant
GB2183637A (en) Chemical compounds
BE796101A (fr) Derives de quinoleine et leur prepration
CN104650031A (zh) 芳香多环羧酸衍生物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150327

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150327

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151007

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20151008

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151223

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160404

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160620

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160721

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20161024

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20161121

R150 Certificate of patent or registration of utility model

Ref document number: 6049216

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250